Merrick, Sophie
Rush, Hannah L.
Daniels, Susanna
Fielding, Alison
Deveson Kell, Sharon
Pickering, Lisa http://orcid.org/0000-0002-7579-340X
Langley, Ruth E. http://orcid.org/0000-0002-9706-016X
South, Annabelle http://orcid.org/0000-0001-8912-2001
Gilbert, Duncan C.
Funding for this research was provided by:
Cancer Research UK (RCCCTF-Nov21\100002, RCCCTF-Nov21\100002)
RCUK | Medical Research Council (MC_UU_00004/02, MC_UU_00004/02, MC_UU_00004/02, MC_UU_00004/02)
RCUK | MRC | Medical Research Foundation (MC_UU_00004/02)
Article History
Received: 18 January 2024
Revised: 29 May 2024
Accepted: 6 June 2024
First Online: 17 June 2024
Competing interests
: Authors SM, RL, LP and DCG work on the REFINE trial (DCG is the Chief Investigator, RL and LP are on the Trial Management Group and SM is the study clinician), and SD, SK and AF are involved in REFINE as PPI representatives. REFINE is an ICI optimisation trial, and provided the motivation to conduct this study. The other authors declare no conflicts of interest.
: This study received approval from the University College London ethics committee (Ethics ID: 23347/001). All participants provided written consent. The research was conducted in accordance with the Declaration of Helsinki.
: All participants gave informed consent for the use of anonymised quotes in publications. To preserve anonymity, real names have been replaced with study identification numbers.